Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President and Chief Executive Officer Luis Peña and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular gl